Estados Unidos · Bolsa y Finanzas · Morningstar

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Publicado por Morningstar · Estados Unidos hace 9 h

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in ...

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

También te puede interesar

Federal Watchdog Investigates Adam Kinzinger for Kalshi Bets on His Pardon

Power Play

Oil prices drop as G7 nations pledge to release diesel stocks; Saudis said planning attack on Houthis

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Compartir

También te puede interesar

Federal Watchdog Investigates Adam Kinzinger for Kalshi Bets on His Pardon

Power Play

Oil prices drop as G7 nations pledge to release diesel stocks; Saudis said planning attack on Houthis

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration